Abstracts tagged "pulmonary complications and rheumatoid arthritis (RA)"

Abstract Number: 1519 • 2015 ACR/ARHP Annual Meeting
Pleuropulmonary Manifestations in Rheumatoid Arthritis Patients
Suzan Attar¹ and Omar Amoudi², ¹Internal Medicine, MBBCH. FRCPC. ABIM, Jeddah, Saudi Arabia, ²Internal Medicine, FRCPC, Jeddah, Saudi Arabia
Background/Purpose: Pulmonary involvement in rheumatoid arthritis (RA) patients is associated with high morbidity and mortality. Nevertheless, limited data are available regarding such lung complications in…
Abstract Number: 2369 • 2013 ACR/ARHP Annual Meeting
Long-Term Outcome Of Infliximab Therapy In Rheumatoid Arthritis Patients: Results From Japanese Multicenter Registry System
Nobunori Takahashi¹, Toshihisa Kojima², Atsushi Kaneko³, Yuji Hirano⁴ and Naoki Ishiguro¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, ³Orthopedic Surgery, Nagoya Medical Center, Nagoya, Japan, ⁴Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan
Background/Purpose: After demonstration of effectiveness of anti-tumor necrosis factor (TNF) agents in patients with rheumatoid arthritis (RA), their use has become common practice in treating…
Abstract Number: 2170 • 2012 ACR/ARHP Annual Meeting
Methotrexate and Interstitial Lung Disease in Rheumatoid Arthritis – A Systematic Literature Review and Meta-Analysis
Richard Conway¹, Candice Low², Robert J. Coughlan³, Martin O'Donnell⁴ and John J. Carey³, ¹Rheumatology, St James's Hospital, Dublin, Ireland, ²Medicine, St. James Hospital, Dublin, Ireland, ³Rheumatology, Galway University Hospitals, Galway, Ireland, ⁴Clinical Research Facility, Galway University Hospitals, Galway, Ireland
Background/Purpose: Methotrexate is commonly prescribed for a variety of diseases including rheumatoid arthritis. Methotrexate has frequently been implicated as a causative agent in interstitial lung…
Abstract Number: 1217 • 2012 ACR/ARHP Annual Meeting
Decreased Survival in Rheumatoid Arthritis Complicated with Bronchiectasis: A Family-Based Cohort Study
Xavier Puéchal¹, Emmanuelle Génin², Thierry Bienvenu³ and Daniel J. Dusser⁴, ¹National Referral Center for Rare Systemic Auto-immune Diseases, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ²Biostatistics, INSERM UMR-S946, Université Paris Diderot, Paris, France, ³Biochemistry and Molecular Biology, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ⁴Respiratory Diseases, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
Background/Purpose: In cystic fibrosis, mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene lead to diffuse bronchiectasis (DB) and decreased survival. DB is also…
Abstract Number: 1227 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis-Associated Interstitial LUNG Disease: Clinical Spectrum of A Large Cohort From A Respiratory Referral Center
Joshua J. Solomon¹, Gloria M. Russell², Jill B. Ketzer³, Amy L. Olson³, Evans R. Fernandez-Perez³, Tristan J. Huie³, Jeffrey J. Swigris³, Kevin K. Brown⁴ and Aryeh Fischer⁵, ¹Autoimmune Lung Center, Denver, ²Pontificia Universidad Católica Madre y Maestra, Santiago, Dominican Republic, ³Autoimmune Lung Center, National Jewish Health, Denver, CO, ⁴Autoimmune Lung Center, National Jewish Hospital, Denver, CO, ⁵Rheumatology / ILD Program, National Jewish Health, Denver, CO
Background/Purpose: Rheumatoid arthritis (RA) has a myriad of pulmonary manifestations and RA-associated interstitial lung disease (RA-ILD) causes the most clinical concern. Subclinical ILD may be…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].